TY  - JOUR
AU  - Berclaz, Luc M
AU  - Jurinovic, Vindi
AU  - Burkhard-Meier, Anton
AU  - Abdel-Rahman, Sultan
AU  - Albertsmeier, Markus
AU  - Klein, Alexander
AU  - Dürr, Hans Roland
AU  - Schmidt-Hegemann, Nina-Sophie
AU  - Knösel, Thomas
AU  - Kunz, Wolfgang G
AU  - Stutz, Emanuel
AU  - von Bergwelt-Baildon, Michael
AU  - Di Gioia, Dorit
AU  - Lindner, Lars H
TI  - Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score-Matched Analysis.
JO  - Cancer medicine
VL  - 14
IS  - 4
SN  - 2045-7634
CY  - Hoboken, NJ
PB  - Wiley
M1  - DKFZ-2025-00437
SP  - e70655
PY  - 2025
AB  - Dacarbazine is currently considered the better combination partner for doxorubicin compared to ifosfamide for the treatment of leiomyosarcoma (LMS). Regional hyperthermia (RHT) combined with neoadjuvant chemotherapy has been shown to improve survival in patients with locally advanced high-risk STS. We sought to evaluate the role of doxorubicin and dacarbazine (AD) versus doxorubicin and ifosfamide (AI) in combination with RHT in patients with LMS.Patients with locally advanced high-grade LMS, including limited metastases, eligible for RHT and first-line treatment with either AI + RHT or AD + RHT between 2014 and 2022 were retrospectively evaluated. Endpoints were progression-free survival (PFS) and overall survival (OS). Patients were matched using propensity scores, which were estimated with a logistic regression model accounting for tumor site, presence of metastasis, surgery, and radiotherapy.A total of 105 patients were included in this study, of which 101 were included in the propensity score-matched cohort. In the matched cohort, treatment with AD + RHT was associated with a significantly improved PFS (HR 0.32, 95
KW  - Humans
KW  - Male
KW  - Female
KW  - Doxorubicin: administration & dosage
KW  - Doxorubicin: therapeutic use
KW  - Ifosfamide: administration & dosage
KW  - Ifosfamide: therapeutic use
KW  - Middle Aged
KW  - Leiomyosarcoma: drug therapy
KW  - Leiomyosarcoma: therapy
KW  - Leiomyosarcoma: pathology
KW  - Leiomyosarcoma: mortality
KW  - Propensity Score
KW  - Antineoplastic Combined Chemotherapy Protocols: therapeutic use
KW  - Antineoplastic Combined Chemotherapy Protocols: adverse effects
KW  - Retrospective Studies
KW  - Aged
KW  - Dacarbazine: administration & dosage
KW  - Dacarbazine: therapeutic use
KW  - Hyperthermia, Induced: methods
KW  - Adult
KW  - Progression-Free Survival
KW  - Combined Modality Therapy
KW  - chemotherapy (Other)
KW  - leiomyosarcoma (Other)
KW  - regional hyperthermia (Other)
KW  - soft tissue sarcoma (Other)
KW  - Doxorubicin (NLM Chemicals)
KW  - Ifosfamide (NLM Chemicals)
KW  - Dacarbazine (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40007213
DO  - DOI:10.1002/cam4.70655
UR  - https://inrepo02.dkfz.de/record/299477
ER  -